Accès direct au contenu


logo du site ENS

Retour à l'accueil du site


Accueil  >  Projects > Project Directors


Xiaotao LI

Xiaotao LI, Ph. D, Professor
East China Normal University
Tel: +86-21-54345018

Dr. Li received his Ph. D. at the University of Texas MA Anderson Cancer Center in 2001. Following his postdoctoral training, he took a faculty position at Baylor College of Medicine and received numerous grant awards including NIHR01. Dr. Li pioneered the biological study of the REGgamma proteasome degradation pathway (Cell, 2006; Mol. Cell, 2007). When returned to China at the end of 2007, he dedicated to intensive and extensive analysis of this proteasome degradation pathway with support from National Natural Science Foundation and the Ministry of Science and Technology of China, Shanghai Educational Department, Science and Technology Commission of Shanghai Municipality.

Dr. Li lead a research team focusing on the protein degradation pathway mediated by the REGγ- proteasome following his initial discovery of a couple of REGγ targets. The long term goal of this team is to extensively understand the biological actions of the REGγ-proteasome and its pathological roles in various human diseases when functions anomaly. Currently, progress are made in the identification of REGγ substrates including p53 (JCS, 2010; J Virology, 2010), regulation of REGγ activity by post-translational modification (Cell Res, 2011), correlation between REGγ and multiple carcinogenic signaling (BMC Cancer 2012), as well as biological studies (JBC, PNAS, 2013). Our efforts are empowering this field as a promising research area, though it's just a beginning. To address further scientific questions in more details, we have initiated various projects using REGγ deficient animal models, revealing the involvement of REGγ-proteasome in multiple biological processes such as neuronal functions, male reproduction, auto-immunity, metabolism, autophagy, aging and cancer progression.

Selected Publications

1.    Liu S, Lai L, Zuo Q, Dai F, Wu L, Wang Y, Liu M, Yi Z, Xiao J, Li X*. PKA turnover by the REGγ-proteasome modulates FoxO1 cellular activity and VEGF-induced angiogenesis. J Mol Cell Cardiol. 2014 Feb 20; 72C: 28-38.

2.    Shi J, Wong J, Piesik P, Fung G, Zhang J, Jagdeo J, Li X, Jan E, Luo H. Cleavage of sequestosome 1/p62 by an enteroviral protease results in disrupted selective autophagy and impaired NFKB signaling. Autophagy. 2013 Aug 13;9 (10).

3.    Ali A, Wang Z, Ji L, Liu J, Li L, Yang Y, Wang Y, Zhou L, Guo L, Wang H, Chen J, Caulin C, Myers JN, Fu J, Xiao J, Zhang B, Li X*. WT-p53/TGF-β signaling and mutant-p53 differentially regulates REGγ to target ubiquitin/ATP-independent REGγ-proteasome pathway during cancer progression. Nature Communication 2013 4:2667

4.    Dong S, Jia C, Zhang S, Fan G, Xiao W, Shan P, Sun L, Li L, Zheng Y, Liu J, Li Y, Wei H, Hu C, Zhang W, Li Q, Liu J, Jia F, Mo Q, Edwards DP, Huang S, Chan L, O'Malley BW, Li X* and Wang C* The REGγ Proteasome Regulates Hepatic Lipid Metabolism through Inhibition of Autophagy. Cell Metabolism 2013 Sep 3;18(3):380-91. 

5.    Li L, Zhao D, Wei H, Yao L, Dang Y, Amjad A, Xu J, Liu J, Guo L, Li D, Li Z, Zuo D, Zhang Y, Liu J, Huang S, Jia C, Wang L, Wang Y, Xie Y, Luo J, Zhang B, Luo H, Donehower LA, Moses RE, Xiao J, O'Malley BW, Li X*. REGγ deficiency promotes premature aging via the casein kinase 1 pathway. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11005-10.

6.    Liu J, Wang Y, Li L, Zhou L, Wei H, Zhou Q, Liu J, Wang W, Ji L, Shan P, Wang Y, Yang Y, Jung SY, Zhang P, Wang C, Long W, Zhang B, Li X*. Site-specific acetylation of the proteasome activator REGγ directs its heptameric structure and functions. J Biol Chem. 2013 Jun 7;288(23):16567-78

7.    Redfern AD, Colley SM, Beveridge DJ, Ikeda N, Epis MR, Li X, Foulds CE, Stuart LM, Barker A, Russell VJ, Ramsay K, Kobelke SJ, Li X, Hatchell EC, Payne C, Giles KM, Messineo A, Gatignol A, Lanz RB, O'Malley BW, Leedman PJ. RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators. Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6536-41. 

8.    Jing He, Long Cui, Yu Zeng, Guangqiang Wang, Li X*. (2012). REGgamma is associated with multiple oncogenic pathways in human cancers. BMC Cancer. Feb 23; 12(1):75.

9.    Wu Y, Wang L, Zhou P, Wang G, Li X*. (2011). Regulation of REG cellular distribution and function by SUMO modification. Cell Research. 2011 May; 21(5):807-16.

10.   Gao G, Wong J, Zhang J, Mao I, Shravah J, Wu Y, Xiao A, Li X*, Luo H. (2010). Proteasome Activator REG Enhances Coxsackieviral Infection via Facilitating p53 Degradation. J. Virol. 84 (21): 11056-11066.

11.   Liu J, Yu G., Zhao P., Wang C., Luo H., Long W., Wang Y., Zhao Y., Tsai M., O'Malley B.W. and Li X*. (2010). REGγ modulates p53 activity by regulating its cellular localization. J. Cell Science. 123 (pt23): 4076-84.

12.   Yu G, Zhao Y, He J, Mukherjee A, Mao CA, Li M, and Li X*. (2008). Comparative analysis of REGγ expression augurs functional implication. J. Mol. Cell. Biol. Aug; 2(4):192-8.

13.   Ivy Mao, Jian Liu, Li X*, Honglin Luo. (2008). REG, A Proteasome Activator and Beyond? Cell and Mol Life Sci. Dec;65(24):3971-80.

14.   Li X*, Larbi Amazit, Weiweng Long, David M. Lonard, John J. Monaco and O’Malley B.W. (2007). Proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol. Cell, 26, 831-842.

15.   Li X*., Lonard D., Jung S.Y., Malovannaya A., Feng Q., Qin J., Tsai S. Y., Tsai M-J., and O’Malley B.W. (2006). The SRC-3/AIB1 coactivator is degraded in an ubiquitin- and ATP-independent manner by the REGgamm-proteasome Cell. 124, 381-392. 



Top of the page

Last update December 14, 2020
Ens de Lyon
15 parvis René Descartes - BP 7000 69342 Lyon Cedex 07 - FRANCE
Tél. : Site René Descartes (siège) : +33 (0) 4 37 37 60 00 / Site Jacques Monod : +33 (0) 4 72 72 80 00